2 编号：2026-003 投资者关系活 动类别 ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 及人员姓名 工银瑞信基金管理有限公司 秦聪 马丁 国海证券股份有限公司 李宇宸 时间 2026 年 2 月 27 日 15：00-15：40 地点 电话会议 上市公司接待 人员姓名 邓百娇女士 董事、董事会秘书 吴 弘先生 证券事务代表 齐鑫鑫女士 投资者关系管理 IR 投资者关系活 动主要内容介 绍 Q1、请简要介绍一下公司的产品结构情况。 A：目前公司产品主要分为医疗器械类产品与功能性护肤 品两大板块，从剂型上主要分贴片类与非贴片类，非贴片类涵 盖水、精华、乳液、喷雾、冻干及次抛精华等多种形态。 Q2、公司非贴片类产品占比情况如何？ A：上海研发中心成立后，我们在化妆品产品方面上新速 度持续加快，产品与剂型不断丰富，在产品结构进一步完善的 同时，非贴片类产品的收入占比也在不断提升。 Q3、公司的三类医疗器械产品进展情况如何？ A：目前我们进展比较快的主要是重组Ⅲ型人源化胶原蛋 白冻干纤维、重组Ⅲ型人源化胶原蛋白贴 ...

Core Viewpoint - Northeast Pharmaceutical is implementing a "one body, two wings" development strategy to enhance resilience and profitability amid industry challenges and market competition [1] Group 1: Operational Efficiency and Market Strategy - The company is focusing on improving operational quality and market expansion, with a steady increase in core business foundations [2] - By 2025, the company aims for multiple breakthroughs in market layout, with core products achieving historical sales highs and brand influence steadily increasing [2] - The raw materials segment is adapting to market fluctuations by optimizing sales structures and expanding into emerging fields, solidifying its market position [2] Group 2: Production and Quality Control - Northeast Pharmaceutical has achieved cost reduction and efficiency improvements while maintaining a 100% product pass rate for factory output and inspections [3] - The company is enhancing production efficiency through process optimization, equipment upgrades, and management improvements [3] Group 3: Research and Innovation - The company is driving growth through both generic and innovative drugs, with three new generic products approved for market by March 2025 [3] - Ongoing projects in biopharmaceuticals and health products are being developed, including new health-oriented products like functional skincare items [3] Group 4: Strategic Development Framework - The "one body, two wings" strategy aims to strengthen the core business of chemical generics while expanding into biopharmaceuticals and traditional Chinese medicine [4] - The company plans to enhance its competitive advantage and market influence across all business segments, focusing on key product sales and overseas promotion of certified products [4] Group 5: Support Systems for Strategy Implementation - To ensure the effective implementation of the "one body, two wings" strategy, the company is optimizing management mechanisms and enhancing operational efficiency [5] - The focus is on risk management, cost control, and digital transformation to improve overall business quality [5] Group 6: Future Growth Drivers - The core growth drivers for the company include the successful transformation of innovative research results and the internationalization of the raw materials business [6] - Digital management and efficiency improvements are also seen as positive factors for driving performance growth [6]

● 本报记者 宋维东 东北制药相关负责人日前在接受中国证券报记者采访时表示，面对行业调整、市场竞争加剧等多重挑 战，公司将锚定"一体两翼"发展战略，坚持稳健经营与创新突破并举，深耕医药核心主业，拓展多元赛 道，打造更多盈利增长点，持续增强发展韧性。 运营质效持续提升 "在药品集采常态化、医保改革持续深化、行业竞争日趋激烈的背景下，东北制药紧扣'变、干、实'工 作总要求，主动适应行业变革，在经营提质、市场拓展、生产增效、研发创新等方面协同发力，发展质 效稳步提升，核心业务根基持续夯实。"该负责人说。 2025年，公司市场布局多点突破，营销效能持续释放。其中，制剂板块聚焦核心产品，深耕终端市场， 渠道覆盖与市场渗透力不断增强，多款主导产品销量创历史新高，新开发终端与主要品种覆盖率均同比 增长，品牌影响力稳步提升。此外，原料药板块积极应对国内外市场波动，通过优化产品销售结构、拓 展新兴领域等举措，核心产品市场地位不断稳固，海外市场持续拓展。该负责人表示，公司各子公司协 同发力，部分子公司成功扭亏为盈，构筑起多元协同、稳健向好的发展格局。 在生产运营方面，东北制药实现降本增效与质量管控双线提升。公司构建了"产销协同、 ...

新华财经上海2月6日电大韩皮肤健康产业协会6日在上海成立。据悉，该平台旨在为韩国企业进入中国市场、深化中韩产业合作提供系统性支持。 业内人士指出，国内消费者对皮肤健康管理与高品质产品需求持续攀升，中国市场对韩国产业界展现强劲吸引力。 上海韩国商会会长卓钟翰表示，中国皮肤健康市场正在经历快速变革与消费升级，医疗、美容、功能性护肤品、健康食品等板块加速融合。 韩国皮肤健康产品协会会长孙弦我表示，皮肤健康产业作为融合医学、生物科技与消费的重要领域，正处于政策与市场的双重红利期。韩国在皮肤科学研 究、临床经验积累以及成果产业化方面拥有优势，而中国则具备庞大的临床资源、快速的技术转化能力。中韩在皮肤健康领域开展合作，可以实现优势互 补。 - - 0 65 l 112 4 .. 0 - 1 - 1 7 and and the program of an : 图为大韩皮肤健康产业协会在沪成立仪式 以产业协会成立为契机，中韩双方将加强技术落地与人才交流，有望孵化一批科研机构、医院与企业之间的联合项目。 韩国保健产业振兴院中国代表处首席代表白承洙表示，协会将成为韩企获取中国皮肤健康市场动向、政策信息及本地合作伙伴的关键节点，积 ...

Core Viewpoint - Fuhua Jia (301371) is a specialized skin care product company focused on the research, production, and sales of professional skin care products, which are divided into medical device products and functional skin care products [1] Group 1: Product Offerings - The company's product forms include masks, waters, serums, lotions, sprays, freeze-dried products, and single-use serums [1] Group 2: Sales Strategy - The company employs an omnichannel strategy for sales, integrating both online and offline channels [1] - Online channels include major e-commerce and social media platforms such as Tmall, Douyin, JD.com, and Pinduoduo [1] - Offline channels penetrate cosmetic specialty stores, large supermarkets, chain pharmacies, beauty institutions, and medical institutions, creating a comprehensive market reach network [1]

Investment Rating - The report assigns a "Trading Buy" rating for the company, indicating a potential upside of 5% to 15% from the current price [5][9]. Core Insights - The company is expected to achieve a net profit of between RMB 270 million and RMB 320 million in 2025, representing a year-on-year increase of 55% to 84%. The fourth quarter of 2025 is projected to show a turnaround with a net profit of RMB 20 million to RMB 70 million [5]. - The company has implemented significant reforms, leading to improved operational efficiency and a reduction in sales expense ratio by over 30% year-on-year. This has resulted in a marginal improvement in business operations [8]. - For 2026, the company anticipates continued operational improvements, with stable growth in its raw materials business and a positive trend in its medical terminal products, which saw a 14.5% year-on-year revenue increase in Q3 2025 [8]. Financial Summary - The company forecasts net profits of RMB 310 million, RMB 530 million, and RMB 600 million for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 76.4%, 72%, and 13.3% [8]. - Earnings per share (EPS) are projected to be RMB 0.64, RMB 1.10, and RMB 1.24 for the same years, with corresponding price-to-earnings (P/E) ratios of 70, 41, and 36 [8]. - The company's revenue is expected to be RMB 4.895 billion in 2025, with a gradual increase to RMB 5.980 billion by 2027 [11].

Investment Rating - The report assigns a "Trading Buy" rating for the company, indicating a potential upside of 5% to 15% from the current price [5][9]. Core Insights - The company is expected to achieve a net profit of between RMB 270 million and RMB 320 million in 2025, representing a year-on-year increase of 55% to 84%. The fourth quarter of 2025 is projected to show a turnaround with a net profit of RMB 20 million to RMB 70 million [5]. - The company has implemented significant reforms, leading to improved operational efficiency and a reduction in sales expense ratio by over 30% year-on-year. This has resulted in a marginal improvement in business operations [8]. - For 2026, the company anticipates continued operational improvements, with stable growth in its raw materials business and a positive trend in its medical terminal products, which saw a 14.5% year-on-year revenue increase in Q3 2025 [8]. Financial Summary - The company forecasts net profits of RMB 310 million, RMB 530 million, and RMB 600 million for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 76.4%, 72%, and 13.3% [8]. - Earnings per share (EPS) are projected to be RMB 0.64, RMB 1.10, and RMB 1.24 for the same years, with corresponding price-to-earnings (P/E) ratios of 70, 41, and 36 [8]. - The company's revenue is expected to decline to RMB 4.895 billion in 2025 before recovering to RMB 5.315 billion in 2026 and RMB 5.980 billion in 2027 [11].

Group 1: Company Strategy - The company focuses on the "big health" development strategy in pharmaceuticals and medical services, aiming to create a comprehensive health ecosystem covering the entire lifecycle of customers [2] - It aims to enhance core competitiveness by concentrating on its main business and improving management levels across various sectors [3] Group 2: Financial Performance - The company forecasts a net profit attributable to shareholders for 2025 between CNY 660 million and CNY 730 million, representing a year-on-year growth of 320.74% to 344.16% [2] - The net profit after deducting non-recurring gains and losses is expected to be between CNY 600 million and CNY 670 million, indicating a growth of 277.59% to 298.31% compared to the previous year [2] Group 3: Pharmaceutical Business - The pharmaceutical segment includes the development, production, and sales of drug formulations and active pharmaceutical ingredients (APIs), with a focus on skin, anti-infection, and anti-tumor products [4] - The company has established three major API production bases, ensuring a stable supply of core products and achieving integration of API and formulation production [4] Group 4: Research and Development - The company emphasizes R&D in pharmaceuticals, focusing on generic drugs in dermatology and specialty medications, while also investing in innovative drugs through its subsidiary [5] - It holds a 13.2% stake in a company specializing in cell gene therapy, making it the third-largest shareholder [5] Group 5: Medical Services - The company has developed a layered business ecosystem in healthcare, providing integrated medical services that include basic medical care, rehabilitation, and longevity health services [6] - It operates hospitals and health management centers, focusing on disease treatment and health improvement [6][7] Group 6: Health Management - The company has established three longevity and anti-aging centers in major cities, implementing a comprehensive management system for health assessment and intervention [7] - It has partnered with global anti-aging pioneer Bryan Johnson to launch the "Blueprint" anti-aging brand, enhancing its service offerings [8] Group 7: Shareholder Returns - The company has maintained a high dividend policy, distributing approximately CNY 3 billion since 2018, and plans to continue sustainable profit distribution [9] - It is considering diverse dividend methods in the future based on its financial performance [9] Group 8: Bond Issuance - The company plans to issue exchangeable bonds totaling no more than CNY 1 billion, subject to market conditions and shareholder approval [9]

Core Viewpoint - The article discusses the crisis faced by the century-old brand "Zhang Xiaoqin," highlighting the stark contrast between the brand's operational success and the financial troubles of its parent company, Fuchun Holdings, which is burdened with over 5 billion yuan in debt [4][6]. Group 1: Brand Crisis and Debt Issues - The auction of a ten-year-old Mercedes-Benz belonging to Zhang Xiaoqin Group reflects the brand's current struggles, as the vehicle's price dropped from 600,000 yuan to 384,000 yuan without attracting buyers [4]. - Zhang Xiaoqin Co., as a listed entity, reported revenue and profit growth for the first three quarters of 2025, indicating that the core business is not failing; rather, the issues stem from the parent company's debt crisis [6][9]. - Fuchun Holdings' aggressive expansion into high-leverage sectors like real estate and finance has led to a complex web of cross-shareholding and guarantees, dragging Zhang Xiaoqin Group into a debt quagmire [8][9]. Group 2: Impact of Diversification - The brand's core foundation is being eroded due to resource misallocation, as the parent company's focus has shifted away from the traditional knife and scissors business to real estate and capital operations [9][10]. - Negative publicity surrounding the parent company's debt issues has tarnished the brand's reputation, leading to consumer doubts about product quality and stability [10]. - The judicial freezing and pledging of 28.23% of the listed company's shares owned by Zhang Xiaoqin Group highlight the financial strain and the potential loss of control over the brand [10]. Group 3: Lessons from Other Brands - The article draws parallels with other brands that have faced similar crises due to blind diversification, such as Renhe Pharmaceutical and Two-Sided Needle, which diluted their core business and brand value [12][13]. - Successful recovery strategies often involve a painful return to core competencies, as demonstrated by Bosideng's focus on down jackets after diversifying unsuccessfully [15][20]. - The case of GAP in China illustrates the effectiveness of deep localization and strategic restructuring in revitalizing a struggling brand [18]. Group 4: Strategic Insights - Brands must respect their core business and focus on deepening their unique value proposition rather than pursuing broad diversification [20][21]. - Successful diversification should stem from natural extensions of core capabilities rather than arbitrary cross-industry ventures [21]. - The article emphasizes the importance of maintaining brand independence and security in capital partnerships to avoid becoming collateral damage in financial games [21].

来源：野马财经 三年半花掉1亿线上推广服务费。 宫腔镜、剖腹产、卵巢囊肿切除术等妇科手术，除了能帮助女性解决病痛外，也可能在术后造成宫腔粘 连、盆（腹）腔粘连等并发症，为了防止这一情况的发生，随着医学的发展，出现了以透明质酸钠材料 为核心的术后防粘连产品。 常州百瑞吉生物医药股份有限公司（下称"百瑞吉"，874637.BJ）就是一家主营宫腔、盆（腹）腔、鼻 （窦）腔术后防粘连产品的医疗器械企业。1月21日，百瑞吉已通过北交所的上会审核"大考"。 事实上，由于百瑞吉的产品所属的术后防粘连市场较为细分，行业市场空间相对有限，近年来，公司积 极开拓"第二增长曲线"，新增功能性护肤品的生产及销售业务，但这部分业务在高营销投入下持续亏 损，尚未实现盈利。 01# 做防粘连产品年入2亿， 覆盖约600家三甲医院 防粘连产品是妇科手术的重要一环。它能从源头预防粘连、促进愈合，是保护女性术后健康和生育力的 关键。 这便是百瑞吉的核心业务领域——防粘连医疗器械。《招股书》显示，百瑞吉的防粘连产品广泛应用于 宫腔、盆（腹）腔及鼻（窦）腔等创伤修复领域，可显著降低患者粘连后二次手术或发生并发症所带来 的身体负担和医疗费用负担，减少 ...